Pacira BioSciences, Inc. (NASDAQ:PCRX) enjoyed a 48.2% run-up in share price since hitting record low of $30. The stock managed 3.49% rise and now stands at $44.46 as of 5/30/2019. At a recent session, the prices were hovering between $43 and $44.83. This company shares are 22.96% off its target price of $54.67 and the current market capitalization stands at $1.84B. The recent change has given its price a 7.52% lead over SMA 50 and -19.16% deficit over its 52-week high. The stock witnessed 11.65% gains, 7.97% gains and -8.73% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found PCRX’s volatility during a week at 3.3% and during a month it has been found around 3.96%.

Pacira BioSciences, Inc. (PCRX) Top Holders

Institutional investors currently hold around $1.77 billion or 0% in PCRX stock. Look at its top three institutional owners: Vanguard Group Inc owns $168.47 million in Pacira BioSciences, Inc., which represents roughly 9.16% of the company’s market cap and approximately 9.5% of the institutional ownership. Similar statistics are true for the second largest owner, Consonance Capital Management Lp, which owns 3,652,134 shares of the stock are valued at $156.9 million. The third largest holder is Blackrock Inc., which currently holds $142.48 million worth of this stock and that ownership represents nearly 7.74% of its market capitalization.

Pacira BioSciences, Inc. 13F Filings

At the end of March reporting period, 112 institutional holders increased their position in Pacira BioSciences, Inc. (NASDAQ:PCRX) by some 7,288,757 shares, 97 decreased positions by 6,278,123 and 34 held positions by 27,718,425. That puts total institutional holdings at 41,285,305 shares, according to SEC filings. The stock grabbed 35 new institutional investments totaling 3,427,441 shares while 34 institutional investors sold out their entire positions totaling 1,434,002 shares.

Pacira BioSciences, Inc. (NASDAQ:PCRX) Insider Trades

Multiple company employees have indulged in significant insider trading. Pacira BioSciences, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director Kronenfeld Mark A. has acquired 1,700 shares of Pacira BioSciences, Inc. (PCRX) in the trading session dated Mar. 06, 2019. These shares are worth $66,249 and were traded at $38.97 each. The SEC filing shows that Wicki Andreas performed a sale of 14,527 shares. The Director disposed these shares by way of transaction on Dec. 13, 2018. The company’s shares were given away at $46.84 per share worth to an income of some $680,445 to the account of Wicki Andreas.

Director, PACE GARY W, purchased 4,500 common shares of Pacira BioSciences, Inc. (PCRX) in the open market. In a transaction dated Nov. 19, 2018, the shares were bought at an average price of $46.18, giving away a sum of $207,810. After this purchase, 32,819 common shares of PCRX are directly owned by the insider, with total stake valued at $1,459,133.

In the transaction dated Nov. 19, 2018, a great number of shares sold came courtesy the Director; Wicki Andreas disposed a total of 990 shares at an average price of $47.08, amounting to approximately $46,609. The insider now directly owns 964,889 shares worth $42,898,965.

Pacira BioSciences, Inc. (PCRX) Analyst Guide

Several analysts have released their opinion on Pacira BioSciences, Inc. (NASDAQ:PCRX), with 2 analysts believing it is a strong buy. Whereas 8 of them predict the stock is a hold. Also, there are 5 buy, 0 sell and 0 strong sell ratings, collectively assigning a 2.4 average brokerage recommendation [T1].